On January 26, 2016, the FDA published a draft guidance entitled “Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices.” The document provides medical device manufacturers with assistance regarding product design and labeling of interoperable devices.
Interoperable medical devices are two or more devices that exchange data and information in a safe and effective manner. The ability to do this is a growing need within the healthcare industry, which is what drove the FDA to develop this draft guidance.
When the draft guidance was released in late January, the FDA asked interested persons to submit comments and suggestions by March 28, 2016. In response to a number of requests for an extension, on February 23rd, the FDA announced that the comment period will remain open for an additional 30 days. As such, interested persons should submit comments, questions, and/or concerns by April 28, 2016.
February 24, 2016
On Wednesday, October 27th, FDA revoked Life Technologies Corporation’s Emergency Use Authorization (EUA) for its TaqPath COVID-19 MS2 Combo Kit 2.0. Background On August 2, 2021, FDA issued an EUA...
February 24, 2016
On Thursday, September 13th, FDA published a proposed rule which would amend the current premarket submission requirements for medical devices. Background In July 2012, the Food and Drug...
February 24, 2016
FDA released proposed regulation that would allow sponsors to determine if their product is a drug/device, or if it is not a drug/device. Last week, the Agency announced a proposed rule “to provide...